Suppr超能文献

尽管在日本南部地区,人们接触黄曲霉毒素 B1 的水平较低,但肝癌患者的肝内黄曲霉毒素 B1-DNA 加合物和 TP53 突变仍然存在。

Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.

机构信息

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Liver Int. 2011 Oct;31(9):1366-72. doi: 10.1111/j.1478-3231.2011.02572.x. Epub 2011 Jun 28.

Abstract

BACKGROUND & AIMS: Hepatitis B or C virus infection is considered to be the main cause of hepatocellular carcinoma (HCC) in Japan. Aflatoxin B1 (AFB1) is a carcinogen associated with HCC in regions with high exposure. Mutations in codon 249, exon 7 are a hallmark of AFB1 exposure. Therefore, to clarify the role of AFB1 in hepatocarcinogenesis, we examined AFB1-DNA in liver tissue and sequenced TP53 in Japanese patients with HCC.

METHODS

Hepatocyte AFB1-DNA adducts were determined immunohistochemically and direct sequencing of TP53 was done to determine mutations in 188 of 279 patients who underwent hepatic resection for HCC. We assessed hepatitis C virus antibodies (HCV Ab) and HBSAg expression; patients without either were defined as having non-B non-C hepatocellular carcinoma (NBNC HCC).

RESULTS

AFB1-DNA adducts were detected in hepatocyte nuclei in 18/279 patients (6%), including 13/83 patients (16%) with NBNC HCC and 5/51 patients (10%) expressing hepatitis B surface antigen. None of the patients with HCV Ab (n=136) were positive for AFB1-DNA. The incidence of the G-T transversion and mutations in exon 7 of TP53 in patients with AFB1-DNA adducts were significantly higher in patients with than in patients without AFB1-DNA adducts. All three patients with the codon 249 AGG-AGT mutation had AFB1-DNA adducts.

CONCLUSION

Although exposure to AFB1 is thought to be low in Japan, it is still associated with hepatocarcinogenesis, particularly in NBNC HCC and hepatitis B individuals.

摘要

背景与目的

乙型肝炎或丙型肝炎病毒感染被认为是日本肝细胞癌(HCC)的主要病因。黄曲霉毒素 B1(AFB1)是与高暴露地区 HCC 相关的致癌物质。密码子 249 外显子 7 的突变是 AFB1 暴露的标志。因此,为了阐明 AFB1 在肝癌发生中的作用,我们检测了日本 HCC 患者肝组织中的 AFB1-DNA,并对 279 例接受肝切除术的 HCC 患者中的 188 例进行了 TP53 的直接测序。

方法

通过免疫组织化学法检测肝细胞 AFB1-DNA 加合物,并对 188 例接受 HCC 肝切除术的患者进行 TP53 直接测序。我们评估了丙型肝炎病毒抗体(HCV Ab)和 HBSAg 表达;无两者的患者被定义为非乙型肝炎非丙型肝炎肝细胞癌(NBNC HCC)。

结果

在 279 例患者中的 18 例(6%)肝细胞核中检测到 AFB1-DNA 加合物,包括 83 例 NBNC HCC 患者中的 13 例(16%)和 51 例乙型肝炎表面抗原表达患者中的 5 例。无 HCV Ab(n=136)的患者均为 AFB1-DNA 阳性。AFB1-DNA 加合物阳性患者的 G-T 颠换和 TP53 外显子 7 突变的发生率明显高于无 AFB1-DNA 加合物阳性患者。所有 3 例密码子 249 AGG-AGT 突变患者均有 AFB1-DNA 加合物。

结论

尽管日本认为 AFB1 的暴露水平较低,但它仍与肝癌发生有关,尤其是在 NBNC HCC 和乙型肝炎个体中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验